CVS: $315 Million Opioid Settlement Resolves Federal Claims

• CVS Pharmacy Inc. has agreed to pay $315 million to resolve federal claims related to its role in the opioid crisis.
• Federal prosecutors alleged CVS filled prescriptions from known "pill mill practices" and then sought reimbursement from federal healthcare programs, violating the False Claims Act.
• The settlement also addresses claims of CVS Controlled Substances Act violations and ignoring warnings from its own pharmacists.
• CVS will implement increased monitoring and safeguards for opioid prescribing patterns as part of the agreement.
• This federal action follows a 2022 settlement where CVS paid nearly $5 billion to state and local governments for similar opioid-related claims.

The consistent federal enforcement, particularly involving the False Claims Act and Controlled Substances Act, signals a continued aggressive stance against pharmaceutical retailers for inadequate oversight of dispensing practices.

CVS Pharmacy Inc. has agreed to a substantial $315 million settlement to resolve federal allegations that it contributed to the national opioid crisis. The pharmaceutical giant, based in Rhode Island, faced claims that it haphazardly dispensed prescriptions for highly addictive opioid painkillers, often originating from questionable sources. Federal prosecutors specifically highlighted instances where CVS allegedly filled prescriptions from prescribers known to be involved in "pill mill practices," characterized by the loose issuance of controlled substance prescriptions without adequate medical justification.

Furthermore, the government contended that after filling these illicit prescriptions, CVS then sought reimbursement from federal healthcare programs, including Medicare, Medicaid, and TRICARE. This practice, according to the Department of Justice, constituted a violation of the False Claims Act. The company was also accused of disregarding explicit warnings from its own pharmacists, who had reportedly urged against filling scripts from suspicious prescribers. In response to the settlement, a CVS spokesperson stated that the company has implemented "best-in-class and first-of-their-kind programs" to support pharmacists' decision-making, while also asserting a strong disagreement with the claims and emphasizing that the settlement with the DOJ admits no wrongdoing.

The $315 million CVS opioid settlement specifically addresses a December 2024 complaint filed by the Justice Department. This complaint detailed accusations that CVS "fed dependence and addiction" on potent opioids through the dispensing of excessive and unlawful prescriptions, subsequently seeking payment from federal health insurance programs. The 97-page civil complaint, lodged in Rhode Island federal court, explicitly alleged that CVS knowingly filled controlled substance prescriptions that lacked a legitimate medical purpose, were invalid, or were not issued within the usual course of professional practice.

These actions, federal prosecutors asserted, represented a clear CVS Controlled Substances Act violation. The period of alleged misconduct spanned from October 17, 2013, to December 2, 2025, during which the company purportedly sought payment for many of these invalid prescriptions from federal healthcare programs, thereby violating the False Claims Act. The Department of Justice further claimed that CVS exacerbated its misconduct through understaffing, a practice that allegedly prioritized profit over patient safety and led its pharmacies to dispense controlled substances based on invalid prescriptions. This aggressive DOJ CVS opioid enforcement highlights the government's focus on holding pharmacies accountable for their role in the opioid crisis.

Assistant Attorney General Brett A. Shumate of the Justice Department’s Civil Division underscored the significance of this resolution, stating that the settlement mandates CVS to implement additional safeguards. These measures are designed to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate, thereby enhancing pharmacy opioid prescription monitoring. Shumate emphasized that these "remedial measures," including proactive monitoring of opioid prescribing patterns, will offer crucial protections for both patients and federal healthcare programs. He affirmed the Department of Justice's ongoing commitment to preventing the unlawful dispensing of opioids.

This recent action follows a previous agreement in 2022 where CVS committed to paying nearly $5 billion to settle thousands of similar claims brought by state and local governments. In that earlier deal, as with the current federal settlement, the company did not admit to any misconduct. The consistent federal enforcement, particularly involving the False Claims Act and Controlled Substances Act, signals a continued aggressive stance against pharmaceutical retailers for inadequate oversight of dispensing practices. This ongoing scrutiny underscores the critical need for robust internal controls and comprehensive prescription monitoring systems across the industry to avoid significant financial penalties and federal enforcement actions.

This settlement highlights the Department of Justice's continued aggressive enforcement against pharmacies for inadequate oversight of opioid dispensing, particularly under the False Claims Act and Controlled Substances Act. Compliance officers in pharmaceutical retail and distribution must urgently review internal controls, staffing levels, and prescription monitoring systems to prevent similar federal enforcement actions and significant financial penalties.

Source: Original reporting via the Associated Press and Courthouse News Service